(Total Views: 828)
Posted On: 07/23/2020 1:47:42 PM
Post# of 155843
Just finished THE KING'S SPEECH I mean
listening to the CYDY call again
.
.
Please note..........and rest assured.............that I am...........and my whole team at cytodyn is...............,very energized..............,we are energized more than ever.............
and we will not stop working very hard until we explore..................every avenue and every indication for Leronlimab potential..............to help mankind.................we are honored to serve you the shareholders................and I thank you for giving us this opportunity..............
.
.
Other than technical difficulties, the call went very well,
Results seem significant SAE ( Serious Adverse Events ) appear to be reduced by the drug Leronlimab
They appear to be bringing on experts for the scientific advisory board and for assistance in designing new trials
Results are complex and should be out shortly
FDA may have DSMB take a peek in the PII/III soonthe interim look is near enrollment regardless. 163 patients enrolled; the 195 mark is in the design/ the protocal for the interim analysis
But this study may lead to approval sooner than anticipated.
Nothing negative Everything seems to be moving forward as good or better than anticipated..x.x...
listening to the CYDY call again
.
.
Please note..........and rest assured.............that I am...........and my whole team at cytodyn is...............,very energized..............,we are energized more than ever.............
and we will not stop working very hard until we explore..................every avenue and every indication for Leronlimab potential..............to help mankind.................we are honored to serve you the shareholders................and I thank you for giving us this opportunity..............
.
.
Other than technical difficulties, the call went very well,
Results seem significant SAE ( Serious Adverse Events ) appear to be reduced by the drug Leronlimab
They appear to be bringing on experts for the scientific advisory board and for assistance in designing new trials
Results are complex and should be out shortly
FDA may have DSMB take a peek in the PII/III soonthe interim look is near enrollment regardless. 163 patients enrolled; the 195 mark is in the design/ the protocal for the interim analysis
But this study may lead to approval sooner than anticipated.
Nothing negative Everything seems to be moving forward as good or better than anticipated..x.x...
(4)
(1)
